Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $1.4 million.

  • Spero Therapeutics' Accounts Payables fell 7709.36% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 7709.36%. This contributed to the annual value of $7.3 million for FY2024, which is 43018.87% up from last year.
  • Per Spero Therapeutics' latest filing, its Accounts Payables stood at $1.4 million for Q3 2025, which was down 7709.36% from $780000.0 recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Accounts Payables ranged from a high of $7.3 million in Q4 2024 and a low of $583000.0 during Q1 2023
  • Its 5-year average for Accounts Payables is $2.5 million, with a median of $1.7 million in 2022.
  • As far as peak fluctuations go, Spero Therapeutics' Accounts Payables tumbled by 8780.33% in 2023, and later skyrocketed by 45213.06% in 2024.
  • Quarter analysis of 5 years shows Spero Therapeutics' Accounts Payables stood at $1.1 million in 2021, then plummeted by 43.96% to $617000.0 in 2022, then soared by 123.34% to $1.4 million in 2023, then surged by 430.19% to $7.3 million in 2024, then crashed by 80.91% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $780000.0 for Q2 2025, and $1.8 million during Q1 2025.